Effectiveness of Clopidogrel Resinate in PCI(PRIDE)

Exclusion Criteria

• •The patient has a known hypersensitivity or contraindication to any of the following medications:
• •* Heparin
• •* Aspirin
• •* Both Clopidogrel and Ticlopidine
• •* Stainless steel and/or
• •* Contrast media (patients with documented sensitivity to contrast which can be effectively pre-medicated with steroids and diphenylhydramine \[e.g. rash\] may be enrolled. Patients with true anaphylaxis to prior contrast media, however, should not be enrolled).
• •Coronary anatomy not amenable to stent placement
• •Female of childbearing potential, unless a recent pregnancy test is negative, who possibly plan to become pregnant any time after enrollment into this study.
• •History of bleeding diathesis or known coagulopathy (including heparin-induced thrombocytopenia), or will refuse blood transfusions.
• •Gastrointestinal or genitourinary bleeding within the prior 3 months, or major surgery within 2 months.
• •Current known current platelet count \<100,000 cells/mm3 or Hgb \<10 g/dL.
• •An elective major surgical procedure is planned that would necessitate interruption of thienopyridines during the first 1 year post enrollment.
• •Non-cardiac co-morbid conditions are present with life expectancy \<1 year or that may result in protocol non-compliance (per site investigator's medical judgment).
• •Patients who are actively participating in another drug or device investigational study, which have not completed the primary endpoint follow-up period.
• •Administration of the following medications prior to randomization: GpIIb-IIIa inhibitor and clopidogrel within 7 days (already received pretreatment), or thrombolytics within 24 hours.
• •Long-term (at least \> 3 months) use or requirement of NSAID or anticoagulation
• •Patients with cardiogenic shock
• •Acute MI patients within symptom onset \< 12 hours needing primary angioplasty
• •Patients with left main stem stenosis (\>50% by visual estimate)